Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 1
2005 3
2006 2
2007 3
2008 4
2009 4
2010 6
2011 7
2012 1
2013 5
2014 5
2015 2
2016 1
2017 1
2018 2
2019 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

45 results
Results by year
Filters applied: . Clear all
Page 1
Pegvisomant in acromegaly: an update.
Giustina A, Arnaldi G, Bogazzi F, Cannavò S, Colao A, De Marinis L, De Menis E, Degli Uberti E, Giorgino F, Grottoli S, Lania AG, Maffei P, Pivonello R, Ghigo E. Giustina A, et al. J Endocrinol Invest. 2017 Jun;40(6):577-589. doi: 10.1007/s40618-017-0614-1. Epub 2017 Feb 7. J Endocrinol Invest. 2017. PMID: 28176221 Free PMC article. Review.
BACKGROUND: In 2007, we published an opinion document to review the role of pegvisomant (PEG) in the treatment of acromegaly. Since then, new evidence emerged on the biochemical and clinical effects of PEG and on its long-term efficacy and safety. ...The number of patients …
BACKGROUND: In 2007, we published an opinion document to review the role of pegvisomant (PEG) in the treatment of acromegaly. Since t …
Effects of medical therapies for acromegaly on glucose metabolism.
Urbani C, Sardella C, Calevro A, Rossi G, Scattina I, Lombardi M, Lupi I, Manetti L, Martino E, Bogazzi F. Urbani C, et al. Eur J Endocrinol. 2013 Jun 7;169(1):99-108. doi: 10.1530/EJE-13-0032. Print 2013 Jul. Eur J Endocrinol. 2013. PMID: 23660641
Among 50 consecutive acromegalic patients under SSA therapy, acromegaly in 19 patients was controlled. PEG used in combination with SSA therapy allowed the control of acromegaly in the remaining 31 patients and was then continued as monotherapy in 18 patients. ...Co …
Among 50 consecutive acromegalic patients under SSA therapy, acromegaly in 19 patients was controlled. PEG used in combination with S …
Correction to: Pegvisomant in acromegaly: an update.
Giustina A, Arnaldi G, Bogazzi F, Cannavò S, Colao A, De Marinis L, De Menis E, Degli Uberti E, Giorgino F, Grottoli S, Lania AG, Maffei P, Pivonello R, Ghigo E. Giustina A, et al. J Endocrinol Invest. 2018 Feb;41(2):267. doi: 10.1007/s40618-017-0800-1. J Endocrinol Invest. 2018. PMID: 29285678 Free PMC article.
The beneficial effect of acromegaly control on blood pressure values in normotensive patients.
Sardella C, Urbani C, Lombardi M, Nuzzo A, Manetti L, Lupi I, Rossi G, Del Sarto S, Scattina I, Di Bello V, Martino E, Bogazzi F. Sardella C, et al. Clin Endocrinol (Oxf). 2014 Oct;81(4):573-81. doi: 10.1111/cen.12455. Epub 2014 May 5. Clin Endocrinol (Oxf). 2014. PMID: 24661019
OBJECTIVE: Control of acromegaly may ameliorate blood pressure (BP) in hypertensive (HT) patients. ...MEASUREMENTS: Blood pressure was measured by clinical measurement and 24-h ambulatory monitoring at diagnosis and after 24 months of medical therapy for acromegaly. …
OBJECTIVE: Control of acromegaly may ameliorate blood pressure (BP) in hypertensive (HT) patients. ...MEASUREMENTS: Blood pressure wa …
Analysis of voice in patients with untreated active acromegaly.
Bogazzi F, Nacci A, Campomori A, La Vela R, Rossi G, Lombardi M, Fattori B, Bartalena L, Ursino F, Martino E. Bogazzi F, et al. J Endocrinol Invest. 2010 Mar;33(3):178-85. doi: 10.1007/BF03346578. J Endocrinol Invest. 2010. PMID: 20418653
BACKGROUND: Voice changes are common clinical findings of acromegaly, although scanty data are available so far. OBJECTIVE: To analyze features and quantify changes of voice in patients with untreated active acromegaly. ...PATIENTS: Thirteen consecutive patients (8 …
BACKGROUND: Voice changes are common clinical findings of acromegaly, although scanty data are available so far. OBJECTIVE: To analyz …
Disease activity and lifestyle influence comorbidities and cardiovascular events in patients with acromegaly.
Sardella C, Cappellani D, Urbani C, Manetti L, Marconcini G, Tomisti L, Lupi I, Rossi G, Scattina I, Lombardi M, Di Bello V, Marcocci C, Martino E, Bogazzi F. Sardella C, et al. Eur J Endocrinol. 2016 Nov;175(5):443-53. doi: 10.1530/EJE-16-0562. Epub 2016 Aug 15. Eur J Endocrinol. 2016. PMID: 27528501
OBJECTIVE: The primary objective of this study is to identify the predictors of comorbidities and major adverse cardiovascular events (MACE) that can develop after diagnosis of acromegaly. The role of therapy for acromegaly in the event of such complications was als …
OBJECTIVE: The primary objective of this study is to identify the predictors of comorbidities and major adverse cardiovascular events (MACE) …
Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline.
Giustina A, Ambrosio MR, Beck Peccoz P, Bogazzi F, Cannavo' S, De Marinis L, De Menis E, Grottoli S, Pivonello R. Giustina A, et al. J Endocrinol Invest. 2014 Oct;37(10):1017-30. doi: 10.1007/s40618-014-0146-x. Epub 2014 Sep 23. J Endocrinol Invest. 2014. PMID: 25245336 Free PMC article. No abstract available.
Apoptosis is reduced in the colonic mucosa of patients with acromegaly.
Bogazzi F, Russo D, Locci MT, Chifenti B, Ultimieri F, Raggi F, Cosci C, Sardella C, Costa A, Gasperi M, Bartalena L, Martino E. Bogazzi F, et al. Clin Endocrinol (Oxf). 2005 Dec;63(6):683-8. doi: 10.1111/j.1365-2265.2005.02405.x. Clin Endocrinol (Oxf). 2005. PMID: 16343104
PATIENTS AND METHODS: Eleven patients with active, untreated acromegaly (AcroUntr), 16 patients with acromegaly in remission (AcroRem) and 23 controls were enrolled in the study. ...CONCLUSION: In conclusion, patients with AcroUntr have reduced apoptosis in colonic …
PATIENTS AND METHODS: Eleven patients with active, untreated acromegaly (AcroUntr), 16 patients with acromegaly in remission ( …
Acromegaly: effects on bone metabolism and mass.
Bogazzi F, Cosci C, Sardella C, Martino E, Gasperi M. Bogazzi F, et al. J Endocrinol Invest. 2005;28(10 Suppl):33-5. J Endocrinol Invest. 2005. PMID: 16550720 Review.
Does pegvisomant treatment expertise improve control of resistant acromegaly? The Italian ACROSTUDY experience.
Cannavo S, Bogazzi F, Colao A, De Marinis L, Maffei P, Gomez R, Graziano E, Monterubbianesi M, Grottoli S; “Italian Acrostudy Group”. Cannavo S, et al. J Endocrinol Invest. 2015 Oct;38(10):1099-109. doi: 10.1007/s40618-015-0289-4. Epub 2015 Apr 28. J Endocrinol Invest. 2015. PMID: 25916431
OBJECTIVE: GH receptor antagonist pegvisomant is indicated for treatment of patients with resistant acromegaly. We compared safety and treatment outcomes of pegvisomant therapy in patients managed by Italian centers enrolling less or more than 15 cases in ACROSTUDY, a safe …
OBJECTIVE: GH receptor antagonist pegvisomant is indicated for treatment of patients with resistant acromegaly. We compared safety an …
45 results